Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report
Synopsis
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.
Novo Nordisk AS (NVO) reportedly plans to cut the prices of Ozempic and Wegovy in the U.S. by up to 50% starting in 2027.
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027. This is a 50% reduction compared to the current list price of Wegovy, and about a 34% cut compared to the list price of Ozempic.
“Our hope is that reduced prices will lead to better access and affordability,” Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations, said in an interview, according to the report.
Novo Nordisk shares were down nearly 3% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.